ESMO 2023

TQB2450: A Quick Look at Its R&D Progress and Clinical Results from the 2023 ESMO_ASIA

27 December 2023
4 min read

On 2 Dec 2023, the latest clinical trial about TQB2450 for the treatment for patients with hepatocellular carcinoma at high risk of recurrence was presented in 2023 ESMO_ASIA.

TQB2450's R&D Progress

TQB2450, also called Benmelstobart, is a monoclonal antibody drug that targets PDL1. It has a wide range of therapeutic areas, including neoplasms, infectious diseases, digestive system disorders, endocrinology and metabolic disease, urogenital diseases, respiratory diseases, immune system diseases, hemic and lymphatic diseases, mouth and tooth diseases, skin and musculoskeletal diseases, and otorhinolaryngologic diseases.

图形用户界面, 应用程序, Teams

描述已自动生成

According to the Patsnap Synapse, TQB2450 has reached the highest phase of development, NDA/BLA globally. And the clinical trial distributions for TQB2450 are primarily in China. The key indication is Advanced Lung Non-Small Cell Carcinoma.

表格

描述已自动生成

Detailed Clinical Result of TQB2450

This single group assignment, open-labeled clinical trial (NCT04888546) was designed to evaluate the efficacy and safety of TQB2450 plus anlotinib as a perioperative regimen for the treatment of resectable HCC with a high risk of recurrence.

图形用户界面, 应用程序, Teams

描述已自动生成

In this study, pts with primary resectable HCC who were at high risk of recurrence were enrolled. High-risk features include tumor size >5 cm, multiple tumors ( 3), satellite nodules, and macrovascular invasion (MVI). Before surgery, pts received 3 cycles of TQB2450 (1200 mg, IV, d1, Q3W) plus 2 cycles of anlotinib (10 mg, PO, d1-d14, Q3W). The feasibility of resection was assessed by radiographic imaging. After 30 days of surgery, patients continued combination therapy for 24 weeks. The primary endpoints were pCR and ORR (mRECIST). Secondary endpoints were PFS, OS, and safety. CRAFITY was derived from serum CRP and AFP values at baseline by adding one point each for CRP 1 mg/dL and AFP 100 ng/mL resulting in three categories: CRAFITY-low, 0 points; CRAFITY-intermediate, 1 point; CRAFITY-high, 2 points.

图形用户界面

描述已自动生成

The result showed that as of July 15, 2023, 20 pts were enrolled (median age 61y [31-68], 95% male), 80% had HBV infection. All pts had Child-Pugh class A and ECOG PS 0. 11 (55%) had single (>5 cm) and 9 (45%) had multiple tumors. While n=10 (50%), n=8 (40%), and n=2 (10%) had CRAFITY-low, intermediate and high, respectively. Of 17 evaluable pts, ORR was 29.4% (5/17), 2 PR pts had low and 3 had intermediate CRAFITY scores. 13 pts completed preoperative therapy and underwent hepatic resection, the R0 resection rate was 100% and the pCR rate was 23.1% (3/13). Among the 3 pCR pts, 1 had low and 2 had intermediate CRAFITY scores; 2 had multiple tumors and no pts had MVI. 13 pts had TRAEs and grade 3/4 TRAEs (10%) including one hypertension (grade 3) and one liver damage (grade 4).

It can be concluded that neoadjuvant therapy combining TQB2450 and anlotinib shows promising results, with a tolerable safety profile. The predictive role of the CRAFITY score for HCC prognosis is worth further exploration.

How to Easily View the Clinical Results Using Synapse Database?

If you want to know the other clinical results of popular conferences, please lick on the “Clinical Results” on the homepage of Patsnap Synapse, which provides multi-dimensional screening and filtering of drugs, indications, targets, companies, result evaluation, release date, popular conferences, etc. to help you quickly locate the data you need. 

Select the clinical meeting you are interested in, such as ESMO. In the results, you can quickly locate the data you want to view by indication, phase and drug name. 

图形用户界面, 文本, 应用程序

描述已自动生成

A single result clearly shows important information such as registration number, phase, indication, Sponsor/Collaborator, biomarker, Trial number, dosing regimen and more. 

图形用户界面, 文本, 应用程序

描述已自动生成

If you would like to view more information about this result, you can go to the result detail page by clicking on the title. 

Above the headings, we provide the original source of the outcome data. The basic information is supplemented with more information beyond the list, such as company, study. design, etc. 

图形用户界面, 应用程序, Teams

描述已自动生成

In the important Outcome Measures section, we provide both list and flowchart forms, which are convenient for you to overview the comparison group information and core indicator data. 

图形用户界面, 应用程序, Teams

描述已自动生成

图形用户界面

描述已自动生成

Finally, if you need to download these results, you can conveniently check the check boxes on the left side of the list, or directly click the "Export" button to download the data for personalized analysis and file sharing.

图形用户界面, 应用程序

描述已自动生成

Click on the image below to embark on a brand new journey of drug discovery!

LEO Pharma Inc. has confirmed that the FDA has endorsed Adbry® (tralokinumab-ldrm) to manage adolescents aged 12-17 with moderate to severe eczema
Latest Hotspot
3 min read
LEO Pharma Inc. has confirmed that the FDA has endorsed Adbry® (tralokinumab-ldrm) to manage adolescents aged 12-17 with moderate to severe eczema
27 December 2023
LEO Pharma Inc. has disclosed that the FDA has recently broadened the sanctioned use of Adbry (tralokinumab-ldrm) by authorizing its application for young individuals.
Read →
What is the significance of liposomal drug delivery systems?
Knowledge Base
3 min read
What is the significance of liposomal drug delivery systems?
27 December 2023
Liposomal drug delivery systems are unique formulations that have gained significant attention in recent years due to their ability to enhance the pharmacokinetics and targeting of certain medications.
Read →
Understanding TNF Inhibitors and Methods to Keep Abreast of Their Recent Developments
Understanding TNF Inhibitors and Methods to Keep Abreast of Their Recent Developments
27 December 2023
The development of TNF inhibitors has been a significant advancement in the treatment of autoimmune diseases.
Read →
In the context of gene therapy, what challenges exist in developing effective gene delivery systems?
Knowledge Base
3 min read
In the context of gene therapy, what challenges exist in developing effective gene delivery systems?
27 December 2023
Developing effective gene delivery systems for gene therapy is a significant challenge due to several factors.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.